RA0673

antibody from Oursmab

Targeting: SELP CD62, CD62P, GMP140, GRMP, PADGEM, PSEL

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0673

Provider

Oursmab

Product name

Inclacumab (Biosimilar Reference Antibody) (SELP)

Antibody type

Monoclonal

Description

Inclacumab (development code REGN-728) is an investigational, fully human monoclonal IgG4 antibody being developed to reduce cardiovascular events in patients with atherosclerotic disease, particularly for the prevention of myocardial infarction (heart attack). It functions as a selective inhibitor of P-selectin. By binding with high affinity to P-selectin, inclacumab blocks its interaction with its ligand, P-selectin glycoprotein ligand-1 (PSGL-1). This blockade inhibits a critical early step in the inflammatory cascade that contributes to arterial thrombosis and the progression of atherosclerosis. Specifically, it aims to prevent the adhesion and rolling of leukocytes (white blood cells) on activated endothelial cells and platelets at sites of vascular injury or plaque rupture.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.